Trivium Point Advisory’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.09M | Sell |
45,408
-51,899
| -53% | -$1.36M | 0.1% | 183 |
|
|
2026
Q1 | $2.73M | Sell |
97,307
-7,321
| -7% | -$195K | 0.49% | 46 |
|
|
2025
Q4 | $2.61M | Buy |
104,628
+362
| +0.3% | +$9.13K | 0.26% | 97 |
|
|
2025
Q3 | $2.66M | Buy |
104,266
+67,293
| +182% | +$1.66M | 0.27% | 98 |
|
|
2025
Q2 | $896K | Buy |
36,973
+5,639
| +18% | +$132K | 0.1% | 188 |
|
|
2025
Q1 | $794K | Sell |
31,334
-3,921
| -11% | -$103K | 0.1% | 188 |
|
|
2024
Q4 | $935K | Sell |
35,255
-2,516
| -7% | -$68.2K | 0.12% | 177 |
|
|
2024
Q3 | $1.01M | Sell |
37,771
-2,577
| -6% | -$75.2K | 0.14% | 161 |
|
|
2024
Q2 | $1.13M | Buy |
40,348
+3,960
| +11% | +$109K | 0.17% | 143 |
|
|
2024
Q1 | $1.01M | Sell |
36,388
-3,329
| -8% | -$92.4K | 0.22% | 110 |
|
|
2023
Q4 | $1.14M | Sell |
39,717
-1,419
| -3% | -$42.9K | 0.28% | 103 |
|
|
2023
Q3 | $1.39M | Buy |
41,136
+403
| +1% | +$14.3K | 0.38% | 85 |
|
|
2023
Q2 | $1.49M | Sell |
40,733
-926
| -2% | -$36K | 0.4% | 81 |
|
|
2023
Q1 | $1.7M | Sell |
41,659
-2,893
| -6% | -$125K | 0.46% | 71 |
|
|
2022
Q4 | $2.27M | Buy |
44,552
+1,057
| +2% | +$50.7K | 0.66% | 50 |
|
|
2022
Q3 | $1.87M | Buy |
43,495
+1,010
| +2% | +$49.1K | 0.58% | 54 |
|
|
2022
Q2 | $2.27M | Sell |
42,485
-6,422
| -13% | -$327K | 0.68% | 43 |
|
|
2022
Q1 | $2.59M | Buy |
48,907
+2,353
| +5% | +$122K | 0.57% | 57 |
|
|
2021
Q4 | $2.75M | Buy |
46,554
+906
| +2% | +$44.9K | 0.58% | 62 |
|
|
2021
Q3 | $1.95M | Sell |
45,648
-1,429
| -3% | -$63.3K | 0.46% | 72 |
|
|
2021
Q2 | $1.84M | Buy |
47,077
+80
| +0.2% | +$3.11K | 0.46% | 80 |
|
|
2021
Q1 | $1.7M | Sell |
46,997
-4,238
| -8% | -$150K | 0.46% | 77 |
|
|
2020
Q4 | $1.9M | Sell |
51,235
-4,549
| -8% | -$167K | 0.55% | 57 |
|
|
2020
Q3 | $1.94M | Buy |
55,784
+7,383
| +15% | +$259K | 0.69% | 46 |
|
|
2020
Q2 | $1.58M | Buy |
48,401
+908
| +2% | +$30.8K | 0.63% | 55 |
|
|
2020
Q1 | $1.56M | Buy |
47,493
+2,523
| +6% | +$86K | 0.8% | 47 |
|
|
2019
Q4 | $1.67M | Buy |
44,970
+1,422
| +3% | +$50.7K | 0.65% | 61 |
|
|
2019
Q3 | $1.48M | Buy |
43,548
+434
| +1% | +$15.8K | 0.68% | 67 |
|
|
2019
Q2 | $1.77M | Sell |
43,114
-1,902
| -4% | -$75.5K | 0.79% | 47 |
|
|
2019
Q1 | $1.81M | Sell |
45,016
-639
| -1% | -$25.6K | 0.85% | 40 |
|
|
2018
Q4 | $1.89M | Buy |
+45,655
| New | +$1.9M | 1.15% | 21 |
|
Other funds holding PFE
Trivium Point Advisory's PFE Position: Q2 2026 in Review
Trivium Point Advisory reduced its Pfizer (PFE) stake by 53% in Q2 2026, selling an estimated $1.36M and leaving 45,408 shares worth $1.09M. The position accounts for 0.1% of the portfolio, ranked #183.
Trivium Point Advisory first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.75M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Trivium Point Advisory held 45,408 shares of Pfizer worth $1.09M as of Q2 2026.
- Trivium Point Advisory sold 51,899 Pfizer shares in Q2 2026, an estimated $1.36M.
- Pfizer made up 0.1% of Trivium Point Advisory's portfolio in Q2 2026, its #183 holding.
- Trivium Point Advisory first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Trivium Point Advisory's Pfizer position peaked at $2.75M in Q4 2021.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Trivium Point Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.